

**Name of entity**

Medtech Global Limited
------------------------

<b>ABN</b>		<b>Reporting Period</b>
70 009 203 203		Year ended 31 March 2013
		<b>Previous Corresponding Period</b>
		Year ended 31 March 2012

<b>Contents</b>	<b>Item</b>
Results for Announcement to the market	1
Commentary on Results	2
Consolidated Income Statement	3
Revenue Activities	3.1
Expenses Activities	3.2
Amortisation and Impairment Expenses	3.3
Comparison of Half-Year Profits / (Losses)	3.4
Consolidated Balance Sheet	4
Retained Profits	4.1
Statement of Changes in Equity	5
Consolidated Cash Flow Statement	6
Reconciliation of Cash	6.1
Non-Cash Financing and Investing Activities	6.2
Net Tangible Assets per Ordinary Share	7
Details of Controlled Entities	8
Details of Control Gained Over Entities During the Period	8.1
Accounting Standards	9
Other Information Regarding the Accounts	10
Subsequent Events	11

**1. RESULTS FOR ANNOUNCEMENT TO THE MARKET**

				A\$'000
Revenue	Increase	22%	to	11,814
Total Comprehensive Income / (Loss) after income tax attributable to members	Increase (Loss)	702%	to	(794)
Total Comprehensive Income / (Loss) for the period attributable to members	Increase (Loss)	702%	to	(794)

The directors do not recommend the payment of a dividend.

**2. COMMENTARY ON RESULTS**

Total comprehensive loss after tax of \$794,000 (2012: Loss \$99,000) is reported for the consolidated group for the year ended 31 March 2013. The following table provides a more detailed summary of the performance for the year relative to the result for the corresponding period last year:

	Year ended 31 March 2013 (A\$'000)	Year ended 31 March 2012 (A\$'000)	Percentage Change
<b>Profit / (Loss) before interest, tax, depreciation and amortisation – EBITDA</b>	<b>251</b>	<b>924</b>	<b>(73%)</b>
Less:			
(a) net interest	(17)	25	(168%)
(b) depreciation and amortisation	(1,027)	(932)	10%
<b>Net Profit / (Loss) before tax</b>	<b>(793)</b>	<b>17</b>	<b>(4,765%)</b>
(c) taxation	(22)	(117)	(81%)
<b>Net Profit / (Loss) after tax before other comprehensive income / (loss)</b>	<b>(815)</b>	<b>(100)</b>	<b>715%</b>
<b>Other comprehensive income / (loss)</b>	-	<b>1</b>	<b>(100%)</b>
<b>Total Comprehensive (Income) / Loss after tax attributable to non-controlling interest</b>	<b>21</b>	-	<b>100%</b>
<b>Total Comprehensive Income / (Loss) after tax attributable to members</b>	<b>(794)</b>	<b>(99)</b>	<b>702%</b>

Revenue and expenses for the year increased mainly due to the acquisition of ConSova Corporation, in Denver, USA, in August 2012. Medtech Global Limited's fully owned United States subsidiary, Medtech Holdings USA, Inc., acquired a 51.6% interest in ConSova Corporation.

The primary reason for the acquisition was to augment Medtech Global Limited's existing operations in the USA. ConSova Corporation has well established relationships with USA corporations who provide employer-sponsored health insurance plans to their workforces. Medtech Global Limited plans to leverage these relationships to market its own range of healthcare software solutions.

During the year, Medtech Global continued its commitment to the development of new markets like India and the USA. The US operation of Medtech Global USA, LLC (owned 85% by Medtech Holdings USA, Inc.) contributed approximately \$435,000 of the group's net losses after tax and the Indian operation contributed approximately \$100,000 of the group's net losses after tax.

The company's new Evolution product is now ready to begin Beta testing in New Zealand, following which it will be fully released to the market.

The directors are confident that the investments in product development and in new markets position the group to be able to respond to global opportunities in the upcoming year.

#### ACCOUNTING POLICIES, ESTIMATION METHODS AND MEASUREMENT BASES

Accounting policies, estimation methods, and measurement bases used in this Appendix 4E are consistent with those used in the last half-year and annual report.

#### LOSS PER SHARE

The entity incurred a total comprehensive loss after tax of \$794,000 during the year (2012: Loss \$99,000). The weighted average number of ordinary shares outstanding during the year used in calculation of basic loss per share was 100,248,061.

Basic loss per share for the year was 0.79 cents (2012: Loss per share 0.10 cents).

#### LOSS AND DIVIDENDS PER SHARE (INCLUDING BUY BACKS)

The directors do not recommend the payment of a dividend.

#### SEGMENT RESULTS

##### (a) Industrial Segments

The economic entity operated primarily in the software development and licensing sector.

##### (b) Geographic Segments

	Total Revenue		Total Comprehensive Income/(Loss) After Income Tax Attributed to Shareholders		Total Assets		Total Liabilities		Amortisation & Depreciation	
	2013 A\$'000	2012 A\$'000	2013 A\$'000	2012 A\$'000	2013 A\$'000	2012 A\$'000	2013 A\$'000	2012 A\$'000	2013 A\$'000	2012 A\$'000
Australia	2,347	2,551	(105)	550	13,031	13,391	3,004	2,733	72	50
New Zealand	7,365	7,109	(18)	77	1,892	2,226	(79)	268	229	271
USA	2,102	-	(386)	(35)	1,486	92	1,444	77	19	-
Inter-Segment Eliminations	-	-	(285)	(691)	-	-	-	-	707	611
<b>TOTAL</b>	<b>11,814</b>	<b>9,660</b>	<b>(794)</b>	<b>(99)</b>	<b>16,409</b>	<b>15,709</b>	<b>4,369</b>	<b>3,078</b>	<b>1,027</b>	<b>932</b>

**3. CONSOLIDATED INCOME STATEMENT**

	Current Period A\$'000	Previous Corresponding Period A\$'000
Revenue – refer 3.1 below	11,814	9,660
Expenses - refer 3.2 below	(12,577)	(9,625)
Borrowing Costs	(30)	(18)
<b>Profit / (Loss) before tax</b>	<b>(793)</b>	<b>17</b>
Income tax (expense) / credit	(22)	(117)
Reported Profit / (Loss) after tax	(815)	(100)
Adjusted Profit / (Loss) after tax	(815)	(100)
<b>Net profit / (Loss)</b>	<b>(815)</b>	<b>(100)</b>
Other Comprehensive Income / (Loss)	-	1
<b>Total Comprehensive (Income) / Loss for the period after tax attributable to non-controlling interest</b>	<b>21</b>	<b>-</b>
<b>Total Comprehensive Income / (Loss) for the period after tax attributable to members</b>	<b>(794)</b>	<b>(99)</b>
Basic Profit / (Loss) Per Share	(0.79) cents	(0.10) cents
Diluted Profit / (Loss) Per Share	(0.79) cents	(0.10) cents
Dividends Per Share	n/a	n/a

**NOTES TO THE CONSOLIDATED INCOME STATEMENT**

**3.1 Revenue**

	Current Period A\$'000	Previous Corresponding Period A\$'000
Revenue from Sales	11,801	9,617
Interest Revenue	13	43
<b>TOTAL REVENUE</b>	<b>11,814</b>	<b>9,660</b>

### 3.2 Expenses

	<b>Current Period A\$'000</b>	<b>Previous Corresponding Period A\$'000</b>
Consulting and Contractor Payments	(2,058)	(1,238)
Employee benefits expenses	(5,654)	(4,143)
Depreciation and Amortisation	(1,027)	(932)
Changes in inventories	(413)	(393)
Occupancy costs	(506)	(402)
IT support expenses	(304)	(354)
Telecommunication costs	(343)	(279)
Travelling expenses	(297)	(412)
Management fees to related party	(883)	(905)
Accounting, legal and statutory costs	(493)	(287)
Printing, stationery and postage	(209)	(173)
Impairment of non-trade receivables	(55)	159
Other net expenses	(335)	(266)
<b>TOTAL EXPENSES</b>	<b>(12,577)</b>	<b>(9,625)</b>

### 3.3 Amortisation and Impairment Expenses

	<b>Before tax A\$'000</b>	<b>Amount (after tax) attributable to Members A\$'000</b>
Amortisation of customer relations	707	707
Amortisation of Clinical Audit Tool (CAT) development costs	14	14
<b>Total Amortisation expense</b>	<b>721</b>	<b>721</b>

### 3.4 Comparison of Half –Yearly Profits / (Losses)

	<b>Current Period A\$'000</b>	<b>Previous Corresponding Period A\$'000</b>
Consolidated profit / (loss) after tax attributable to members reported for the 1st half yearly report.	(43)	126
Consolidated profit / (loss) after tax attributable to members for the 2nd half year.	(751)	(225)
<b>TOTAL</b>	<b>(794)</b>	<b>(99)</b>

**4. CONSOLIDATED BALANCE SHEET**

	<b>Current Period A\$'000</b>	<b>Previous Corresponding Period A\$'000</b>
<b>CURRENT ASSETS</b>		
Cash and cash equivalents	845	972
Trade and other receivables	1,315	1,182
Inventories	264	194
Provision for income tax	177	-
Other current assets	155	6
<b>TOTAL CURRENT ASSETS</b>	<b>2,756</b>	<b>2,354</b>
<b>NON-CURRENT ASSETS</b>		
Property, plant & equipment	486	547
Deferred tax assets	366	406
Intangible assets	12,801	12,402
<b>TOTAL NON-CURRENT ASSETS</b>	<b>13,653</b>	<b>13,355</b>
<b>TOTAL ASSETS</b>	<b>16,409</b>	<b>15,709</b>
<b>CURRENT LIABILITIES</b>		
Trade and other payables	2,176	1,495
Unearned revenue	875	892
Short-term borrowings	362	73
Short-term provisions	481	357
Provision for income tax	-	115
<b>TOTAL CURRENT LIABILITIES</b>	<b>3,894</b>	<b>2,932</b>
<b>NON-CURRENT LIABILITIES</b>		
Unearned revenue	-	59
Deferred tax liabilities	125	-
Long-term borrowings	350	87
<b>TOTAL NON-CURRENT LIABILITIES</b>	<b>475</b>	<b>146</b>
<b>TOTAL LIABILITIES</b>	<b>4,369</b>	<b>3,078</b>
<b>NET ASSETS</b>	<b>12,040</b>	<b>12,631</b>
<b>EQUITY</b>		
Contributed equity	48,929	48,929
Foreign currency translation reserve	(96)	(120)
Accumulated losses	(36,972)	(36,178)
Parent interest	11,861	12,631
Minority interest <sup>1</sup>	179	-
<b>TOTAL EQUITY</b>	<b>12,040</b>	<b>12,631</b>

<sup>1</sup> Minority interest represents 15% Non-Controlling Interest in Medtech Global USA, LLC and 48.4% Non-Controlling Interest in ConSova Corporation. All other entities within the group are fully owned by the parent Medtech Global Ltd.

## NOTES TO THE CONSOLIDATED BALANCE SHEET

### 4.1 Consolidated Retained Profits

	Current Period A\$'000	Previous Corresponding Period A\$'000
Adjusted accumulated losses at the beginning of the financial period (see note 5 below)	(36,178)	(36,079)
Profit/(loss) attributable to members	(794)	(99)
Accumulated losses at the end of the financial period	<b>(36,972)</b>	<b>(36,178)</b>

### 5. STATEMENT OF CHANGES IN EQUITY

	Share Capital (Ordinary) A\$'000	Accumulated (Losses) A\$'000	NCI <sup>2</sup> A\$'000	FCTR <sup>3</sup> A\$'000	Total A\$'000
<b>Balance at 1 April 2011</b>	<b>48,929</b>	<b>(36,079)</b>	-	<b>(121)</b>	<b>12,729</b>
Losses attributable to members of parent entity	-	(99)	-	-	(99)
FCTR	-	-	-	1	1
<b>Balance at 1 April 2012</b>	<b>48,929</b>	<b>(36,178)</b>	-	<b>(120)</b>	<b>12,631</b>
Losses attributable to members of parent entity	-	(794)	-	-	(794)
FCTR	-	-	-	24	24
NCI	-	-	179	-	179
<b>Balance at 31 March 2013</b>	<b>48,929</b>	<b>(36,972)</b>	<b>179</b>	<b>(96)</b>	<b>12,040</b>

<sup>2</sup> Non-Controlling Interest (NCI) represents 15% ownership in Medtech Global USA, LLC and 48.4% ownership in ConSova Corporation.

<sup>3</sup> Foreign Currency Translation Reserve.



6. **CONSOLIDATED CASH FLOW STATEMENT**

	<b>Current Period A\$'000</b>	<b>Previous Corresponding Period A\$'000</b>
<b>CASH FLOWS FROM OPERATING ACTIVITIES</b>		
Receipts from customers	12,785	12,088
Payments to suppliers and employees	(11,758)	(11,054)
Interest received	12	43
Finance costs	(22)	(17)
Income tax paid	(408)	(277)
<b>Net operating cash flows</b>	<b>609</b>	<b>783</b>
<b>CASH FLOWS FROM INVESTING ACTIVITIES</b>		
Purchase of property, plant & equipment	(117)	(184)
Purchase of intangible assets	(615)	(1,029)
Payments for acquisition of business	(305)	-
Cash acquired from business combination	211	-
<b>Net investing cash flows</b>	<b>(826)</b>	<b>(1,213)</b>
<b>CASH FLOWS FROM FINANCING ACTIVITIES</b>		
Proceeds from borrowings	212	-
Repayments of borrowings	(121)	(98)
Other	(1)	-
<b>Net financing cash flows</b>	<b>90</b>	<b>(98)</b>
Net increase/(decrease) in cash held	(127)	(528)
Cash at the beginning of the financial year	972	1,500
<b>Cash at the end of the period</b>	<b>845</b>	<b>972</b>

## NOTES TO THE CONSOLIDATED CASH FLOW STATEMENT

### 6.1 Reconciliation of Cash

	Current Period A\$'000	Previous Corresponding Period A\$'000
Cash on hand and at bank	271	204
Deposits at call	574	768
<b>Total cash at end of period</b>	<b>845</b>	<b>972</b>

### 6.2 Non-Cash Financing and Investing Activities

Not applicable.

## 7. NET TANGIBLE ASSET / (LIABILITY) PER ORDINARY SHARE BACKING

	Current Period A\$	Previous Corresponding Period A\$
Net Tangible Asset/(Liability) Per Ordinary Share (NTA/(NTL) backing)	(0.76) cents	0.23 cents

## 8. DETAILS OF CONTROLLED ENTITIES

### 8.1 Control Gained Over Entities During the Period

On 1 August 2012, Medtech Global Limited's fully owned United States subsidiary Medtech Holdings USA, Inc. ("Medtech Holdings"), acquired a 51.6% interest in ConSova Corporation, a limited liability company incorporated in Denver, State of Colorado, USA for US\$651,462. The company paid US\$220,200 in cash on 1 August 2012 and the balance is payable in 42 equal monthly instalments of US\$11,214. The monthly instalment includes interest at 5% per annum on the outstanding balance. As at reporting date, AU\$365,254 is owed to a former owner for the shares in ConSova Corporation that were acquired by Medtech Holdings.

The consolidated statement of comprehensive income includes sales revenue and net profit for the eight months (August 2012 to March 2013) of US\$2,102,148 and US\$88,006 respectively, of which US\$45,411 (51.6%) loss was attributable to owners of the parent. Had the acquisition of ConSova Corporation occurred at the beginning of the reporting period, the consolidated statement of comprehensive income would have included sales revenue and net profit of US\$3,077,722 and US\$114,500 respectively, of which US\$59,082 (51.6%) loss would have been attributable to owners of the parent. During the whole of the previous corresponding period, the sales revenue and net loss of ConSova Corporation was US\$2,500,282 and US\$270,357 respectively.

Non-controlling interest in the net tangible assets of ConSova Corporation was determined on the basis of 48.4% interest held by minority interests.

**9. ACCOUNTING STANDARDS**

Appendix 4E has been prepared in accordance with the recognition and measurement requirements of Australian Accounting Standards, Australian Accounting Interpretations, and other authoritative pronouncements of the Australian Accounting Standards Board.

**10. OTHER INFORMATION REGARDING THE ACCOUNTS**

**10.1 The information contained in the Appendix 4E is based on accounts which:**

- have been audited
- are in the process of being audited
- have not yet been audited

X

**10.2 Audit Disputes or Qualifications**

As at the date of filing, no audit disputes and / or qualifications have been identified.

**11. SUBSEQUENT EVENTS**

Nil.